Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jun;51(6):585–589. doi: 10.1136/thx.51.6.585

Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.

A Grove 1, B J Lipworth 1
PMCID: PMC1090487  PMID: 8693438

Abstract

BACKGROUND: Previous studies have shown that both salmeterol and formoterol act as partial beta 2 receptor agonists in terms of antagonising the extrapulmonary responses to fenoterol in normal subjects. The aim of the present study was to extend previous observations in evaluating the effect of prior treatment with salmeterol and formoterol on bronchodilator responses to fenoterol, a full beta 2 receptor agonist, in patients with asthma. METHODS: Ten stable asthmatic patients of mean (SE) age 37 (3.7) years and forced expiratory volume in one second (FEV1) 59.5 (4.1)% of predicted completed the study. One hour after inhaling single doses of placebo, salmeterol 25 micrograms, or formoterol 12 micrograms, dose-response curves to repeated doses of inhaled fenoterol were constructed (cumulative doses of 100-3200 micrograms). Measurements of airway and systemic beta 2 receptor mediated responses were made at baseline, after inhalation of placebo, salmeterol, or formoterol, and after each dose of fenoterol. RESULTS: Salmeterol and formoterol produced significant bronchodilation compared with placebo (mean difference and 95% CI compared with placebo): FEV1, salmeterol 0.41 (95% CI 0.13 to 0.69) 1, formoterol 0.47 (95% CI 0.19 to 0.75) 1. Salmeterol and formoterol had no significant effect on systemic responses compared with placebo. There were no significant differences in peak airway responses to fenoterol after treatment with salmeterol or formoterol compared with placebo (mean (pooled SE)): FEV1, placebo 2.84 (0.03) 1, salmeterol 2.87 (0.03) 1, and formoterol 2.88 (0.03) 1. There were no significant differences in the area under the dose-response curve for any of the parameters during the dose-response curve following treatment with salmeterol or formoterol compared with placebo. There was no difference in the slope of the dose-response curves to fenoterol for FEV1 or forced expiratory flow (FEF25-75) after treatment with salmeterol or formoterol compared with placebo, although there was a significant (p < 0.05) attenuation of the slope in the dose-response curve for the peak expiratory flow rate (PEFR). CONCLUSIONS: Prior treatment with low doses of salmeterol or formoterol does not significantly alter bronchodilator dose-response curves to repeated doses of fenoterol in stable asthmatic patients.

Full text

PDF
585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson G. P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160. doi: 10.1016/0024-3205(93)90729-m. [DOI] [PubMed] [Google Scholar]
  2. Ball D. I., Brittain R. T., Coleman R. A., Denyer L. H., Jack D., Johnson M., Lunts L. H., Nials A. T., Sheldrick K. E., Skidmore I. F. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991 Nov;104(3):665–671. doi: 10.1111/j.1476-5381.1991.tb12486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Castle W., Fuller R., Hall J., Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993 Apr 17;306(6884):1034–1037. doi: 10.1136/bmj.306.6884.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Derom E. Y., Pauwels R. A. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax. 1992 Jan;47(1):30–33. doi: 10.1136/thx.47.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grove A., Lipworth B. J. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995 Jul 22;346(8969):201–206. doi: 10.1016/s0140-6736(95)91265-7. [DOI] [PubMed] [Google Scholar]
  6. Grove A., Lipworth B. J. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax. 1996 Jan;51(1):54–58. doi: 10.1136/thx.51.1.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Grove A., McFarlane L. C., Lipworth B. J. Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax. 1995 Feb;50(2):134–138. doi: 10.1136/thx.50.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Källström B. L., Sjöberg J., Waldeck B. The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol. 1994 Nov;113(3):687–692. doi: 10.1111/j.1476-5381.1994.tb17047.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lindén A., Bergendal A., Ullman A., Skoogh B. E., Löfdahl C. G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax. 1993 May;48(5):547–553. doi: 10.1136/thx.48.5.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  11. Naline E., Zhang Y., Qian Y., Mairon N., Anderson G. P., Grandordy B., Advenier C. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 1994 May;7(5):914–920. [PubMed] [Google Scholar]
  12. Smyth E. T., Pavord I. D., Wong C. S., Wisniewski A. F., Williams J., Tattersfield A. E. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ. 1993 Feb 27;306(6877):543–545. doi: 10.1136/bmj.306.6877.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Waller D. G. Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy? Br J Clin Pharmacol. 1990 Aug;30(2):157–171. doi: 10.1111/j.1365-2125.1990.tb03760.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES